Fund Holdings — Sarissa Capital Management LP

Total Portfolio Value:
$322.86M
Total Bought:
$2.78M
Total Sold:
$69.79M
Net Transaction:
-$67.01M
Securities
▲▼
SharesValue
Q3 2024
▲▼
Q4 2024
▲▼
Change
▲▼
Q3 2024
▲▼
Q4 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Innoviva, Inc.(INVA)7,277,0007,277,0000$140.52M$126.26M39.11%-$14.26M
Ironwood Pharmaceuticals, Inc.CL A(IRWD)16,390,00016,390,0000$67.53M$72.61M22.49%+$5.08M
Neurocrine Biosciences, Inc.(NBIX)410,483309,116-101,367$47.30M$42.19M13.07%-$5.10M
Cytokinetics, Incorporated(CYTK)1,110,000833,799-276,201$58.61M$39.22M12.15%-$19.39M
Gilead Sciences, Inc.(GILD)763,333262,080-501,253$64.00M$24.21M7.50%-$39.79M
Amarin Corp PlcADR24,850,62324,850,6230$15.58M$12.05M3.73%-$3.53M
Lantheus Holdings, Inc.(LNTH)26,00063,000+37,000$2.85M$5.64M1.75%+$2.78M
Vor Biopharma Inc.(VOR)618,000618,0000$432.6K$686.0K0.21%+$253.4K
Biogen Inc.(BIIB)26,9500-26,950$5.22M$0—-$5.22M
Regulus Therapeutics Inc185,1830-185,183$290.7K$0—-$290.7K
Page 1 of 1
Sarissa Capital Management LP — 13F Holdings — Q4 2024 | TickerTrail